#LCSM Chat Topic 5/7/2020: #COVID19 testing and #lungcancer: Where we stand today

The COVID-19 pandemic is scary, and the situation continues to evolve.  Lung cancer patients and families may have little understanding of COVID-19 testing or how it may affect patient care.  And there is plenty of confusion out there! For our next chat, “COVID-19 testing and lung cancer: Where we stand today,” we will discuss these concerns with pulmonary pathologists and molecular pathologists, who are on the cutting edge of COVID-19 test development and use. Please join #LCSM Chat Thursday, May 7, 2020, at 8 pm Eastern time (5 pm Pacific) to discuss… Read More

#LCSM Chat Topic 4/2/2020: #COVID19 and #LungCancer

It seems that the world has turned upside down.  At the time I write this, there have been almost 550,00 cases of COVID-19 confirmed in the world and over 85,000 in the US.  Here in New York City there have been over 23,000 cases and 365 deaths as of March 27th (https://coronavirus.jhu.edu/map.html). The pandemic has placed enormous stress on our health care delivery system.  For lung cancer patients, it has affected healthcare providers’ ability to perform tests and radiologic procedures; provide timely diagnosis, staging, and care for early stage patients; and, in… Read More

#CANCERSM Chat topic 11-Jul-2019: Basics of Biomarker Testing

Until just a few years ago, chemotherapy was often the only option for some cancer patients.  In just a few short years, molecular therapies and immunotherapies have become commonplace as treatments for cancer patients.  But determining whether a particular cancer patient is a candidate for these new, often very expensive, molecular and immunotherapies requires molecular biomarker testing.  For many cancer patients and their families, the role of molecular biomarker testing in their diagnosis is a unfamiliar and confusing.  How is testing performed?  How is the test result analyzed? What is involved in… Read More